Phase 1 Results of Amgen's BiTE® Platform in Heavily Pre-Treated Patients With Multiple Myeloma and Acute Myeloid Leukemia
FDA Grants Fast Track Designation for AMG 420
PR Newswire
THOUSAND OAKS, Calif., Dec. 3, 2018
PR Newswire
THOUSAND OAKS, Calif., Dec. 3, 2018
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey